Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 389
- Registration Number
- NCT00106366
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Rio Piedras, Puerto Rico
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-02-24
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 503
- Registration Number
- NCT00104182
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valladolid, Spain
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 324
- Registration Number
- NCT00097084
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Ängelholm, Sweden
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
- Conditions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 447
- Registration Number
- NCT00095082
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.